<DOC>
	<DOCNO>NCT02156271</DOCNO>
	<brief_summary>The purpose study help scientist good understand effect 12-week single daily even dose ramelteon ( Rozerem © ) , drug approve U. S. Food Drug Administration ( FDA ) treatment insomnia ( trouble fall asleep stay asleep ) . The study measure level inflammation , fast insulin fast glucose ( sugar ) subject take either ramelteon ( 8 mg ) placebo .</brief_summary>
	<brief_title>Mechanisms Sleep Latency Health : The Effect Melatonin Receptor Agonist Inflammation Insulin Resistance</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Melatonin</mesh_term>
	<criteria>At screen visit : aged 1865 nonsmoker woman : oral contraceptive ( OC ) hormone replacement therapy ( HRT ) nonusers To schedule baseline PSG ( Visit 2 ) , subject must meet follow inclusion criterion : age 1865 inclusive ; PSQIComponent 2 ( sleep latency ) score great 1 ; nonsmoker ( e.g. , less 20 cigarette past 5 year ) ; habitual bedtime 8:30 pm midnight For premenopausal woman : regular menstrual cycle determine Framingham Study criterion ; pregnant history oral contraceptive ( OC ) usage last 6months . For postmenopausal woman : recent ( &lt; 6 month ) use Hormone Replacement Therapy ( HRT ) surgical menopause positive urine drug screen Potential subject hypersensitivity ramelteon component formulation exclude participation . Given ramelteon use individual severe hepatic impairment , patient combination fluvoxamine , individual report liver problem use fluvox exclude . use rifampin ( Rifadin © ) ; ketoconazole ( Nizora ©l ) ; fluconazole ( Diflucan © ) . Ramelteon study child adolescent , effect population unknown , thus individual 18 year participate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Insomnia</keyword>
</DOC>